Expression of MSH2 and MSH6 on a tissue microarray in patients with osteosarcoma

Anticancer Research

Volumn 34, Issue 12, 2014, Pages 6961-6972

  Jentzsch, Thorsten ^a,b   Robl, Bernhard ^a   Husmann, Maren ^a   Bode Lesniewska, Beata ^b   Fuchs, Bruno ^a  

^a BALGRIST UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Chemotherapy responder; Demographics.; Metastasis; MSH2; MSH2 6 TMA; MSH6; Osteosarcoma; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN ANTIBODY; PROTEIN MSH2; PROTEIN MSH6; DNA BINDING PROTEIN; G-T MISMATCH-BINDING PROTEIN; MSH2 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BONE TISSUE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CHILD; CONTROLLED STUDY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; OSTEOSARCOMA; OVERALL SURVIVAL; PRIMARY TUMOR; PROTEIN EXPRESSION; SURVIVAL TIME; TISSUE MICROARRAY; TISSUE SECTION; TREATMENT RESPONSE; ADJUVANT THERAPY; ADOLESCENT; BIOSYNTHESIS; BONE NEOPLASMS; LUNG TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; PRESCHOOL CHILD; SECONDARY; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; DNA-BINDING PROTEINS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTS HOMOLOG 2 PROTEIN; NEOADJUVANT THERAPY; OSTEOSARCOMA; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84918591265     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Ottaviani G and Jaffe N: The epidemiology of osteosarcoma. Cancer Treat Res 152: 3-13, 2009.
2. Picci P: Osteosarcoma (osteogenic sarcoma). Orphanet J Rare Dis 2: 6, 2007.
3. Fletcher CDM, Bridge JA, Hogendoorn P and Mertens F: WHO Classification of Tumours of Soft Tissea and Bone: Osteogenic Tumours. World Health Organization Classification of Tumours Lyon, IARC Press: 275-296, 2013.
4. Dorfman H CB: Bone Tumors. St Louis, Mosby Inc: 128-252, 1998.
5. Marina N, Gebhardt M, Teot L and Gorlick R: Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 9: 422-441, 2004.
6. Carrle D and Bielack SS: Current strategies of chemotherapy in osteosarcoma. Int Orthop 30: 445-451, 2006.
7. Jentzsch T, Erschbamer M, Seeli F and Fuchs B: Extensor function after medial gastrocnemius flap reconstruction of the proximal tibia. Clin Orthop Relat Res 471: 2333-2339, 2013.
8. Sabile AA, Arlt MJ, Muff R, Bode B, Langsam B, Bertz J, Jentzsch T, Puskas GJ, Born W and Fuchs B: Cyr61 expression in osteosarcoma indicates poor prognosis and promotes intratibial growth and lung metastasis in mice. J Bone Miner Res 27: 58-67, 2012.
9. Iwamoto Y, Tanaka K, Isu K, Kawai A, Tatezaki S, Ishii T, Kushida K, Beppu Y, Usui M, Tateishi A, Furuse K, Minamizaki T, Kawaguchi N and Yamawaki S: Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J. J Orthop Sci 14: 397-404, 2009.
10. Chou AJ and Gorlick R: Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther 6: 1075-1085, 2006.
11. Klein MJ and Siegal GP: Osteosarcoma: anatomic and histologic variants. Am J Clin Pathol 125: 555-581, 2006.
12. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, Zoubek A, Jurgens H and Winkler K: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1, 702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20: 776-790, 2002.
13. Gorlick R and Khanna C: Osteosarcoma. J Bone Miner Res 25: 683-691, 2010.
14. Fuchs I: Prognostische Elevanz von p53, Mdm2 und Ki67 beim Osteosarkom. Evaluation mittels Tissue-Micro-Array. In: UniversitäsSpital Züich. Institut f klinische Pathologie. Züich, Switzerland: Medizinische Fakultü der Universitä Züich, pp. 1-63, 2010.
15. Mintz MB, Sowers R, Brown KM, Hilmer SC, Mazza B, Huvos AG, Meyers PA, Lafleur B, McDonough WS, Henry MM, Ramsey KE, Antonescu CR, Chen W, Healey JH, Daluski A, Berens ME, Macdonald TJ, Gorlick R and Stephan DA: An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res 65: 1748-1754, 2005.
16. Somers GR, Ho M, Zielenska M, Squire JA and Thorner PS: HER2 amplification and overexpression is not present in pediatric osteosarcoma: a tissue microarray study. Pediatr Dev Pathol 8: 525-532, 2005.
17. Osborne TS, Ren L, Healey JH, Shapiro LQ, Chou AJ, Gorlick RG, Hewitt SM and Khanna C: Evaluation of eIF4E expression in an osteosarcoma-specific tissue microarray. J Pediatr Hematol Oncol 33: 524-528, 2011.
18. Kim SY and Helman LJ: Strategies to explore new approaches in the investigation and treatment of osteosarcoma. Cancer Treat Res 152: 517-528, 2009.
19. Petrov SV, Machado I, Boulytcheva IV, Noguera R, Pellin A, Bacchini P, Bertoni F and Llombart-Bosch A: New approaches in the diagnosis of small-cell round tumors of bone and soft tissue. Arkh Patol 71: 34-40, 2009.
20. Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A and Picci P: Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 106: 1154-1161, 2006.
21. Bacci G, Mercuri M, Longhi A, Ferrari S, Bertoni F, Versari M and Picci P: Grade of chemotherapy-induced necrosis as a predictor of local and systemic control in 881 patients with nonmetastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy in a single institution. Eur J Cancer 41: 2079-2085, 2005.
22. Buermeyer AB, Deschêes SM, Baker SM and Liskay RM: Mammalian DNA mismatch repair. Annu Rev Genet 33: 533-564, 1999.
23. Peltomäki P and Vasen HF: Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer. Gastroenterology 113: 1146-1158, 1997.
24. Yozu M, Symmans P, Dray M, Griffin J, Han C, Ng D, Parry S and Wong K: Muir-Torre syndrome-associated pleomorphic liposarcoma arising in a previous radiation field. Virchows Arch 462: 355-360, 2013.
25. Scott RH, Mansour S, Pritchard-Jones K, Kumar D, MacSweeney F and Rahman N: Medulloblastoma, acute myelocytic leukemia and colonic carcinomas in a child with biallelic MSH6 mutations. Nat Clin Pract Oncol 4: 130-134, 2007.
26. Urso E, Agostini M, Pucciarelli S, Bedin C, Dangelo E, Mescoli C, Viel A, Maretto I, Mammi I and Nitti D: Soft tissue sarcoma and the hereditary non-polyposis colorectal cancer (HNPCC) syndrome: formulation of an hypothesis. Mol Biol Rep 39: 9307-9310, 2012.
27. Nilbert M, Therkildsen C, Nissen A, Akerman M and Bernstein I: Sarcomas associated with hereditary nonpolyposis colorectal cancer: broad anatomical and morphological spectrum. Fam Cancer 8: 209-213, 2009.
28. Fujii H, Honoki K, Tsujiuchi T, Kido A, Yoshitani K and Takakura Y: Sphere-forming stem-like cell populations with drug resistance in human sarcoma cell lines. Int J Oncol 34: 1381-1386, 2009.
29. Ahmed H, Salama A, Salem SE and Bahnassy AA: A case of synchronous double primary breast carcinoma and osteosarcoma: Mismatch repair genes mutations as a possible cause for multiple early onset malignant tumors. Am J Case Rep 13: 218-223, 2012.
30. Edelbrock MA, Kaliyaperumal S and Williams KJ: Structural, molecular and cellular functions of MSH2 and MSH6 during DNA mismatch repair, damage signaling and other noncanonical activities. Mutat Res 743-744: 53-66, 2013.
31. Peltomäki P and Vasen H: Mutations associated with HNPCC predisposition-Update of ICG-HNPCC/INSiGHT mutation database. Dis Markers 20: 269-276, 2004.
32. Modrich P: Mechanisms in eukaryotic mismatch repair. J Biol Chem 281: 30305-30309, 2006.
33. Gazzoli I and Kolodner RD: Regulation of the human MSH6 gene by the Sp1 transcription factor and alteration of promoter activity and expression by polymorphisms. Mol Cell Biol 23: 7992-8007, 2003.
34. Gassman NR, Clodfelter JE, McCauley AK, Bonin K, Salsbury FR and Scarpinato KD: Cooperative nuclear localization sequences lend a novel role to the N-terminal region of MSH6. PLoS One 6: e17907, 2011.
35. Li GM: The role of mismatch repair in DNA damage-induced apoptosis. Oncol Res 11: 393-400, 1999.
36. Alani E: The Saccharomyces cerevisiae Msh2 and Msh6 proteins form a complex that specifically binds to duplex oligonucleotides containing mismatched DNA base pairs. Mol Cell Biol 16: 5604-5615, 1996.
37. Lamers MH, Perrakis A, Enzlin JH, Winterwerp HH, de Wind N and Sixma TK: The crystal structure of DNA mismatch repair protein MutS binding to a G x T mismatch. Nature 407: 711-717, 2000.
38. Wang H, Yang Y, Schofield MJ, Du C, Fridman Y, Lee SD, Larson ED, Drummond JT, Alani E, Hsieh P and Erie DA: DNA bending and unbending by MutS govern mismatch recognition and specificity. Proc Natl Acad Sci USA 100: 14822-14827, 2003.
39. Jentzsch T, Robl B, Husmann M, Bode-Lesniewska B and Fuchs B: Worse Prognosis of Osteosarcoma Patients Expressing IGF-1 on a Tissue Microarray. Anticancer Res 34: 3881-3889, 2014.
40. Winkler K, Beron G, Delling G, Heise U, Kabisch H, Purfst C, Berger J, Ritter J, Jgens H and Gerein V: Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol 6: 329-337, 1988.
41. Salzer-Kuntschik M, Brand G and Delling G: [Determination of the degree of morphological regression following chemotherapy in malignant bone tumors]. Pathologe 4: 135-141, 1983.
42. Battifora H: The multitumor (sausage) tissue block: novel method for immunohistochemical antibody testing. Lab Invest 55: 244-248, 1986.
43. Di Cristofano C, Leopizzi M, Miraglia A, Sardella B, Moretti V, Ferrara A, Petrozza V and Della Rocca C: Phosphorylated ezrin is located in the nucleus of the osteosarcoma cell. Mod Pathol 23: 1012-1020, 2010.
44. Kononen J, Bubendorf L, Kallioniemi A, Bärlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G and Kallioniemi OP: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4: 844-847, 1998.
45. Camp RL, Charette LA and Rimm DL: Validation of tissue microarray technology in breast carcinoma. Lab Invest 80: 1943-1949, 2000.
46. Ruifrok AC and Johnston DA: Quantification of histochemical staining by color deconvolution. Anal Quant Cytol Histol 23: 291-299, 2001.
47. Scotlandi K, Manara MC, Serra M, Marino MT, Ventura S, Garofalo C, Alberghini M, Magagnoli G, Ferrari S, Lopez-Guerrero JA, Llombard-Bosch A and Picci P: Expression of insulin-like growth factor system components in Ewings sarcoma and their association with survival. Eur J Cancer 47: 1258-1266, 2011.
48. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, Zoubek A, Jürgens H and Winkler K: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1, 702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20: 776-790, 2002.
49. Belloni M, Uberti D, Rizzini C, Jiricny J and Memo M: Induction of two DNA mismatch repair proteins, MSH2 and MSH6, in differentiated human neuroblastoma SH-SY5Y cells exposed to doxorubicin. J Neurochem 72: 974-979, 1999.
50. Heinen CD, Schmutte C and Fishel R: DNA repair and tumorigenesis: lessons from hereditary cancer syndromes. Cancer Biol Ther 1: 477-485, 2002.
51. Cox EC: Bacterial mutator genes and the control of spontaneous mutation. Annu Rev Genet 10: 135-156, 1976.
52. Strand M, Prolla TA, Liskay RM and Petes TD: Destabilization of tracts of simple repetitive DNA in yeast by mutations affecting DNA mismatch repair. Nature 365: 274-276, 1993.
53. Peltomäki P: Deficient DNA mismatch repair: a common etiologic factor for colon cancer. Hum Mol Genet 10: 735-740, 2001.
54. Lin DP, Wang Y, Scherer SJ, Clark AB, Yang K, Avdievich E, Jin B, Werling U, Parris T, Kurihara N, Umar A, Kucherlapati R, Lipkin M, Kunkel TA and Edelmann W: An Msh2 point mutation uncouples DNA mismatch repair and apoptosis. Cancer Res 64: 517-522, 2004.
55. Russo MT, Blasi MF, Chiera F, Fortini P, Degan P, Macpherson P, Furuichi M, Nakabeppu Y, Karran P, Aquilina G and Bignami M: The oxidized deoxynucleoside triphosphate pool is a significant contributor to genetic instability in mismatch repair-deficient cells. Mol Cell Biol 24: 465-474, 2004.
56. Zhang N, Lu X, Zhang X, Peterson CA and Legerski RJ: hMutSbeta is required for the recognition and uncoupling of psoralen interstrand cross-links in vitro. Mol Cell Biol 22: 2388-2397, 2002.
57. Lan L, Hayashi T, Rabeya RM, Nakajima S, Kanno S, Takao M, Matsunaga T, Yoshino M, Ichikawa M, Riele H, Tsuchiya S, Tanaka K and Yasui A: Functional and physical interactions between ERCC1 and MSH2 complexes for resistance to cisdiamminedichloroplatinum( II) in mammalian cells. DNA Repair (Amst) 3: 135-143, 2004.
58. Lin X and Howell SB: DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance. Mol Cancer Ther 5: 1239-1247, 2006.
59. Ting S, Mairinger FD, Hager T, Welter S, Eberhardt WE, Wohlschlaeger J, Schmid KW and Christoph DC: ERCC1, MLH1, MSH2, MSH6, and βIII-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma. Clin Lung Cancer 14: 558-567.e553, 2013.